

Balaxi Pharmaceuticals Limited

November 07, 2022

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Newspaper Advertisement – Disclosure under Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement published today i.e. November 07, 2022, regarding the financial results of the Company for the quarter and half year ended September 30, 2022 as published in Business Standard (English) and Nava Telangana (Telugu) newspapers.

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For Balaxi Pharmaceuticals Limited

Udayan Shukla
(Company Secretary and Compliance Officer)
Membership No.: F11744

Encl: A/a

Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Balaxi Pharmaceuticals Limited

Registered Office: 2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

**EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2022**

(Rs. in Lakhs, unless specified)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter ended 30/09/2022 Unaudited	Six Months ended 30/09/2022 Unaudited	Quarter ended 30/09/2021 Unaudited	Quarter ended 30/09/2022 Unaudited	Six Months ended 30/09/2022 Unaudited	Quarter ended 30/09/2021 Unaudited
1.	Total Revenue from Operations	2,826.47	5,471.83	3,351.16	8,638.48	16,916.97	7,022.97
2.	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	592.38	1,245.66	541.19	1,867.98	3,532.83	1,403.26
3.	Net profit/(loss) for the period before tax (after exceptional and/or extraordinary items)	592.38	1,245.66	541.19	1,867.98	3,532.83	1,403.26
4.	Net profit/(loss) for the period after tax (after exceptional and/or extraordinary items)	397.67	931.19	403.43	1,548.68	2,963.34	1,205.39
5.	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	397.67	931.19	403.43	1,880.73	3,535.98	1,217.25
6.	Paid-up Equity Share Capital [Face value of Rs. 10 each]	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
7.	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year			4,791.30			10,316.39
8.	Earnings Per Share (of Rs.10/- each) (not annualised)						
	1. Basic (amount in Rs.)	3.98	9.31	4.03	15.49	29.63	12.05
	2. Diluted (amount in Rs.)	3.98	9.31	4.03	15.49	29.63	12.05

Notes:

a. The above is an extract of the detailed format of Financial Results for the quarter and half year ended 30th September, 2022 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.

b. The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 5th November, 2022 and have been subjected to Limited Review by the Statutory Auditors of the Company. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of Board of Directors,
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Place: Hyderabad

Date: 5th November, 2022



LAURUS Labs

Knowledge . Innovation . Excellence

AMLESS STEELS LIMITED

B1949PLC017539:

Subhas Road, Kolkata -700001

4019-9595 / 9518:

Website: bhartiabrightandseamless.in

SHAREHOLDERS

ction 108/110 of the Companies Act, 2013, (the 'Act')
ement and Administration) Rules, 2014 (including any
the time being in force) read with the General Circular
13th April, 2020, 20/2020 dated May 05, 2020, 22/2020
ber, 2020, 39/2020 dated 31st December, 2020 and 10/
0/2021 dated December 08, 2021 and General Circular
nition of the framework provided in the aforementioned
Ministry of Corporate Affairs, (hereinafter referred to as
e Board of India Circular Nos. SEBI/HO/CFD/CMD1/
0/ CMD2/CIR/P/2021/11 dated January 15, 2021 and
1, 2022 ("**SEBI Circulars**") and other applicable laws
ard of India (Delisting of Equity Shares) Regulations,
e of the Postal Ballot has been sent on Saturday
names appears on the Register of member / List of
2 through electronic mail to all those members whose
participants in compliance with the General Circulars,
pany by Postal Ballot (remote e-voting only), for the
ry delisting of equity shares of the Company from the
o Securities and Exchange Board of India (Delisting of
nd Exchange Board of India (Listing Obligations and
ended and the applicable provisions of the Companies

Depository Services (India) Limited (CDSL) to provide is providing e-voting facilities to the Members of the materialized form as on the cut-off date to cast their d by CDSL. The manner of remote e-voting has been

High Postal Ballot will open on Sunday 6th November, 2022 at 5.00 P.M.

urohit Proprietor of M/s. Alok Purohit & Associates,
r conducting the Postal Ballot / electronic voting in a
s in physical mode are requested to furnish their email
r and Share Transfer Agent ("RTA") and Members, who
requested to register their email address for receiving
/ with RTA at email id: nichetechpl@nichetechpl.com.

Notice may apply to the Registrar and Share Transfer
 nichetechpl@nichetechpl.com and obtain a duplicate
 Company's website: bhartiabrightandseamless.in and

on the cut-off date i.e. Friday 28th October, 2022. A
ould treat this notice for information purpose only.

within two working days from the last date of e-voting accordingly. The results would be communicated to the Company's website i.e. bhartiabrightandseamless.in.

For any queries, please contact Sri Chandrashekhara Prasad Pandey, Chief Executive Officer of the Company at 033- 4019-9595 / 9518 or email: cs@cdslindia.com. For queries regarding e-voting you may contact to CDSL at Toll Free 1800 222 222 or info@cdslindia.com.

For Bhartia Bright & Seamless Steels Limited
Sd/

Rama Shanker Bhartia
Director (DIN- 00280620)

